Relieves rheumatoid arthritis. ANDA 75280, held by Chartwell Rx. Nabumetone.
As of Nov 15, 2026, ANDA 75280 (Nabumetone), held by Chartwell Rx, was first approved by FDA on Feb 25, 2002, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Carefully consider the potential benefits and risks of nabumetone tablets and other treatment options before deciding to use nabumetone tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Nabumetone tablets, USP are indicated: For relief of the signs and symptoms of rheumatoid arthritis. For relief of the signs and symptoms of osteoarthritis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 25, 2002 | Original application | Approved |
| Nabumetone500MG · tablet;oral | Nabumetone | Rx |
| Nabumetone750MG · tablet;oral | Nabumetone | Rx |
| Nov 21, 2024 | Supplement 27Labeling · Standard review | Approved | None posted |
| Apr 29, 2021 | Supplement 25Labeling · Standard review | Approved | None posted |
| May 9, 2016 | Supplement 24Labeling · Standard review | Approved | None posted |
| Mar 16, 2007 | Supplement 12Labeling | Approved | None posted |
| Feb 23, 2006 | Supplement 11Labeling | Approved | None posted |
| Feb 25, 2002 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters